Mer­ck touts topline PhI­II Keytru­da da­ta in pre-surgery breast can­cer treat­ment

Mer­ck’s block­buster an­ti-PD-1 ther­a­py Keytru­da is inch­ing its way to­ward an­oth­er po­ten­tial in­di­ca­tion, this time a chemother­a­py com­bo pre-surgery in pa­tients with high-risk, ear­ly-stage ER …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER